Cipla's Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire's Firazyr, the company said in a regulatory filing.
Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr.
Cipla also launched a dedicated 24x7 helpline and email channel to support patient access to these critical drugs exclusively during this pandemic outbreak.
Cipremi has been approved by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.
The three drugs are Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin).
The stock has rallied 72 percent in last three months as pharma sector has been in focus during COVID-19 crisis
Earlier, trials were limited to a few people but now we need a larger trial on around 600-700 people, said Shekhar Mande, Director General of CSIR.
Remdesivir is the only United States Food and Drug Administration (USFDA)-approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.
Dr Avi Kumar, Consultant, Pulmonologist, Fortis Escort Heart Institute, said drugs such as Favipiravir and Remdisiver "cannot be called game changers" as they are used as a supportive treatment.
Remdesivir has emerged as one of the most promising drug candidates in the treatment of COVID-19
India's Drug Regulator gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, official sources said.
The two companies have entered into an agreement to provide better access to innovative medicines for patients in India.
In the first stage, subscription of 15,392 compulsorily convertible preference shares and purchase of 6,927 equity shares is expected to be closed within 30 days from the execution date, subject to certain conditions precedent.
Anand Rathi is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 738 in its research report dated May 28, 2020.
"It has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate nasal spray 4mg/mL from the United States Food and Drug Administration (USFDA) with a competitive generic therapy (CGT) designation," the company said in a filing to BSE.
Cipla is reportedly fine tuning its pact with United States-based Gilead Sciences Inc. on patented intravenous drug remdesivir, a potential treatment for the respiratory infection.
HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 655 in its research report dated May 16, 2020.
ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 670 in its research report dated May 18, 2020.
The company has submitted an abbreviated new drug application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the US Food and Drug Administration (USFDA), Cipla said in a regulatory filing.
The company announced the submission of an ANDA for Fluticasone propionate and Salmeterol inhalation powder with the US drug regulator.
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 650 in its research report dated May 15, 2020.
The stock in the past year gained only 2.6 percent and rose 19.2 percent year-to-date.